Information de reference pour ce titreAccession Number: | 00002300-200308000-00015.
|
Author: | MCKENNA, S. P.; COOK, S. A.; WHALLEY, D.; DOWARD, L. C.; RICHARDS, H. L. *; GRIFFITHS, C. E.M. *; VAN ASSCHE, D. +
|
Institution: | Galen Research, Enterprise House, Lloyd Street North, Manchester M15 6SE, U.K. (MCKENNA) (COOK) (WHALLEY) (DOWARD) (*)The Dermatology Centre, University of Manchester, Hope Hospital, Manchester M6 8HD, U.K. +Novartis Pharma AG, Basel, Switzerland
|
Title: | |
Source: | British Journal of Dermatology. 149(2):323-331, August 2003.
|
Abstract: | Background: Patients with psoriasis have significant impairment in their quality of life (QoL). Several patient-completed instruments are available to measure outcome in dermatological conditions but these primarily focus on severity of disease rather than on QoL.
Objectives: To develop a new instrument specifically designed to measure QoL in psoriasis-the Psoriasis Index of Quality of Life (PSORIQoL).
Methods: The content of the instrument was derived from qualitative interviews with 62 psoriasis patients in the U.K., Italy and the Netherlands. Content analysis of the interview transcripts from the three countries identified potential items for the questionnaire. All further stages of the project were conducted in the U.K. only. Face and content validity were determined by means of a focus group held with seven psoriasis patients and face-to-face interviews with a further 21 patients. A new draft version of the PSORIQoL, together with the Dermatology Life Quality Index (DLQI) and the General Well-Being Index (GWBI), were completed by a new sample of psoriasis patients contacted by mail, in order to determine construct validity. A subsample of the respondents completed a similar package 2 weeks later, to assess reproducibility (reliability).
Results: The first version of the PSORIQoL consisted of 61 items covering the needs identified in the interviews as having been affected by psoriasis or its treatment. These included fear of negative reactions from others, self-consciousness and poor self-confidence, problems with socialization, physical contact and intimacy, limitations on personal freedom and impaired relaxation, sleep and emotional stability. Following the focus group and field-test interviews, a new draft measure consisting of 45 items was completed by 148 patients, 88 of whom completed and returned a similar package 2 weeks later. Application of Rasch analysis identified a final 25-item version of the PSORIQoL. This version had a test-retest reliability coefficient of 0[middle dot]89, indicating good reproducibility. The levels of association with the DLQI and PGWB indicated that the PSORIQoL measures a related but distinct construct.
Conclusions: The PSORIQoL appears to be a practical, reliable and valid instrument for measuring the impact of psoriasis on QoL. It remains necessary to establish the instrument's responsiveness to changes in QoL associated with treatment.
(C) 2003 British Association of Dermatologists
|
Author Keywords: | psoriasis; PSORIQoL; quality of life; questionnaire.
|
References: | 1 Gawkrodger DJ on behalf of the Therapy Guidelines and Audit Subcommittee of the British Association of Dermatologists. Current management of psoriasis. J Dermatol Treat 1997; 8: 27-55.
2 Fried RG, Friedman S, Paradis C. Trivial or terrible? The psychosocial impact of psoriasis. Int J Dermatol 1995; 34: 101-5.
3 Hughes JE, Barraclough M, Hamblin LG et al. Psychiatric symptoms in dermatology patients. Br J Psychiatry 1983; 143: 51-4.
4 Jowett S, Ryan T. Skin disease and handicap: an analysis of the impact of skin conditions. Soc Sci Med 1985; 20: 425-9.
5 Fortune DG, Main CJ, O'Sullivan TM et al. Quality of life in patients with psoriasis: the contribution of clinical variables and psoriasis-specific stress. Br J Dermatol 1997; 137: 755-60.
6 Ramsey B, O'Reagan M. A survey of the social and psychological effects of psoriasis. Br J Dermatol 1988; 118: 195-201.
7 Finlay AY, Coles EC. The effect of severe psoriasis on the quality of life of 369 patients. Br J Dermatol 1995; 132: 236-44.
8 Wahl AK, Gjengedal E, Hanestad BR. The bodily suffering of living with severe psoriasis: in-depth interviews with 22 hospitalized patients with psoriasis. Qual Health Res 2002; 12: 250-61.
9 Rapp SR, Feldman SR, Exum ML et al. Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol 1999; 41: 401-7.
10 Nichol MB, Margolis JE, Lippa E et al. The application of multiple quality of life instruments in individuals with mild-to-moderate psoriasis. Pharmacoeconomics 1996; 10: 644-53.
11 McKenna SP, Whalley D, Doward LC. Which outcomes are important in schizophrenia trials? Int J Methods Psychiatr Res 2000; 9(Suppl.): S58-67.
12 Finlay AY, Kelly SE. Psoriasis-an index of disability. Clin Exp Dermatol 1987; 12: 8-11.
13 Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI)-a simple practical measure for routine clinical use. Clin Exp Dermatol 1994; 19: 210-16.
14 Gupta MA, Gupta AK. The Psoriasis Life Stress Inventory: a preliminary index of psoriasis-related stress. Acta Derm Venereol (Stockh) 1995; 75: 240-3.
15 Chren MM, Lasek RJ, Quinn LM et al. Skindex, a quality-of-life measure for patients with skin disease: reliability, validity, and responsiveness. J Invest Dermatol 1996; 107: 707-13.
16 Morgan M, McCreedy R, Simpson J, Hay RJ. Dermatology quality of life scales-a measure of the impact of skin diseases. Br J Dermatol 1997; 136: 202-6.
17 Hunt SM, McKenna SP. The QLDS: a scale for the measurement of quality of life in depression. Health Policy 1992; 22: 307-19.
18 Gill TM, Feinstein AR. A critical appraisal of the quality of quality of life measurements. JAMA 1994; 272: 619-25.
19 Holmes SJ, McKenna SP, Doward LC, Shalet SM. Development of a questionnaire to assess the quality of life of adults with growth hormone deficiency. Endocrinol Metab 1995; 2: 63-9.
20 Wagner TH, Patrick DL, McKenna SP, Froese MA. Cross-cultural development of a quality of life measure for men with erection difficulties. Qual Life Res 1996; 5: 443-9.
21 de Jong Z, van der Heijde D, McKenna SP, Whalley D. The reliability and construct validity of the RAQoL: a rheumatoid arthritis-specific quality of life instrument. Br J Rheumatol 1997; 36: 878-83.
22 McKenna SP, Doward LC, Mackenzie Davey K. The development and psychometric properties of the MSQOL; a migraine-specific quality-of-life instrument. Clin Drug Invest 1998; 15: 413-23.
23 Doward LC, McKenna SP, Kohlmann T et al. The international development of the RGHQoL: a quality of life measure for recurrent genital herpes. Qual Life Res 1998; 7: 143-53.
24 Whalley D, McKenna SP, Dewar AL et al. Quality of life in adults with atopic dermatitis-the international development of the QoLIAD. Qual Life Res 2000; 9: 322.
25 Whalley D, McKenna SP, Dewar AL et al. International development of a measure to assess quality of life in childhood atopic dermatitis-the PIQOL-AD. Qual Life Res 2000; 9: 302.
26 Hunt SM, McKenna SP. A British adaptation of the General Well-Being Index: a new tool for clinical research. Br J Med Econ 1992; 2: 49-60.
27 Andrich D. Rasch Models for Measurement. London: Sage Publications, 1988.
28 Weiner EA, Stewart BJ. Assessing Individuals. Boston: Little, Brown, 1984.
29 Nunally JC Jr. Psychometric Theory, 2nd edn. New York: McGraw-Hill, 1978.
30 Berzon R, Hays RD, Shumaker SA. International use, application and performance of health-related quality of life instruments. Qual Life Res 1993; 2: 367-8.
31 Koo J. Population-based epidemiologic study of psoriasis with emphasis on quality of life assessment. Dermatol Clin 1996; 14: 485-96.
32 Hunt SM. The problem of quality of life. Qual Life Res 1997; 6: 205-12.
33 Tuynman-Qua H, de Jonghe F, McKenna SP. Quality of Life in Depression Scale (QLDS). Development, reliability, validity, responsiveness and application. Eur Psychiatry 1997; 12: 199-202.
34 McKenna SP, Doward LC, Alonso J et al. The QoL-AGHDA. an instrument for the assessment of quality of life in adults with growth hormone deficiency. Qual Life Res 1999; 8: 373-83.
35 Patel R, Tyring S, Strand A et al. Impact of suppressive antiviral therapy on the health related quality of life of patients with recurrent genital herpes infection. Sex Transm Infect 1999; 75: 398-402.
36 Whalley D, Huels J, McKenna SP, vanAssche D. The benefit of pimecrolimus (Elidel(R), SDZ ASM 981) on quality of life in the treatment of mild-to-moderate paediatric atopic eczema. Pediatrics 2002; 110: 1133-6.
37 Krueger GG, Feldman SR, Camisa C et al. Two considerations for patients with psoriasis and their clinicians: what defines mild, moderate and severe psoriasis? What constitutes a clinically significant improvement when treating psoriasis? J Am Acad Dermatol 2000; 43: 281-5.
|
Language: | English.
|
Document Type: | Original articles: Epidemiology and Health Services Research.
|
Journal Subset: | Clinical Medicine.
|
ISSN: | 0007-0963
|
NLM Journal Code: | aw0, 0004041
|
Annotation(s) | |
|
|